Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Rani Therapeutics Holdings (RANI) Receivables - Accured (2022 - 2023)

Rani Therapeutics Holdings' Receivables - Accured history spans 2 years, with the latest figure at $200000.0 for Q4 2023.

  • On a quarterly basis, Receivables - Accured changed 0.0% to $200000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $200000.0, a 0.0% change, with the full-year FY2023 number at $200000.0, changed 0.0% from a year prior.
  • Receivables - Accured came in at $200000.0 for Q4 2023, roughly flat from $200000.0 in the prior quarter.
  • The five-year high for Receivables - Accured was $200000.0 in Q4 2022, with the low at $100000.0 in Q1 2023.